A detailed history of Citigroup Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Citigroup Inc holds 93,338 shares of IMVT stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,338
Previous 31,595 195.42%
Holding current value
$2.57 Million
Previous $834,000 207.79%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$27.51 - $27.51 $1.7 Million - $1.7 Million
61,743 Added 195.42%
93,338 $2.57 Million
Q2 2024

Aug 12, 2024

SELL
$25.1 - $31.61 $5.48 Million - $6.9 Million
-218,196 Reduced 87.35%
31,595 $834,000
Q1 2024

May 10, 2024

BUY
$30.27 - $43.79 $3.8 Million - $5.49 Million
125,449 Added 100.89%
249,791 $8.07 Million
Q4 2023

Feb 09, 2024

SELL
$31.31 - $44.19 $61,805 - $87,231
-1,974 Reduced 1.56%
124,342 $5.24 Million
Q3 2023

Nov 09, 2023

BUY
$18.55 - $39.96 $708,220 - $1.53 Million
38,179 Added 43.32%
126,316 $4.85 Million
Q2 2023

Aug 10, 2023

SELL
$14.2 - $23.75 $2.8 Million - $4.68 Million
-197,230 Reduced 69.11%
88,137 $1.67 Million
Q1 2023

May 11, 2023

BUY
$15.27 - $19.72 $2.79 Million - $3.6 Million
182,796 Added 178.21%
285,367 $4.43 Million
Q4 2022

Feb 09, 2023

BUY
$6.59 - $17.75 $656,443 - $1.77 Million
99,612 Added 3366.41%
102,571 $1.82 Million
Q3 2022

Nov 10, 2022

SELL
$3.93 - $6.37 $10,673 - $17,300
-2,716 Reduced 47.86%
2,959 $17,000
Q2 2022

Aug 10, 2022

BUY
$3.38 - $5.65 $1,193 - $1,994
353 Added 6.63%
5,675 $22,000
Q1 2022

May 12, 2022

SELL
$5.06 - $8.77 $754,835 - $1.31 Million
-149,177 Reduced 96.56%
5,322 $29,000
Q4 2021

Feb 10, 2022

SELL
$7.33 - $9.32 $883,631 - $1.12 Million
-120,550 Reduced 43.83%
154,499 $1.32 Million
Q3 2021

Nov 10, 2021

BUY
$7.01 - $11.37 $1.93 Million - $3.13 Million
275,049 New
275,049 $2.39 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.